Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam Pharmaceuticals, BridgeBio and Pfizer. The phase 2 trial compared two doses of ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Pfizer has won the ...

While most enzymatic activity is conducted through chemical binding interactions between molecules, in some cases, the mere presence of an enzyme can affect intracellular functions. While exploring ...

Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

If brevity is the soul of a hit, Finneas may be about to have his biggest hit ever. Apple commissioned the multiple-Oscar/Grammy winner to write a theme so short that it’s not even being called a ...

SAN FRANCISCO, CA—A treatment strategy that involves a novel sirolimus-eluting balloon (Selution; Cordis) performs as well as standard care when used to treat both de novo coronary artery disease and ...